This site is intended for Healthcare professionals only.

Dr Reddy’s gets USFDA Approval for launching Doxorubicin Hydrochloride Liposome Injection in US

Dr Reddy’s gets USFDA Approval for launching Doxorubicin Hydrochloride Liposome Injection in US

HYDERABAD: Dr. Reddy’s Laboratories Ltd. announced  that it has received approval from the U.S. Food and Drug Administration (USFDA) to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil® (doxorubicin hydrochloride liposome injection), for intravenous use, in the United States market.

USFDA approval is an outcome of extensive collaboration with the company’s partner, Natco Pharma Ltd. on R&D and manufacturing capabilities.

“This approval represents the first of its kind for Dr. Reddy’s in the complex depot injectables arena,” explains Alok Sonig, Executive Vice President and Head of the North America Generics business at Dr. Reddy’s Laboratories. “It is a testament to our commitment to bring affordable generic medicines to market for patients. The approval further validates our capabilities to successfully develop and manufacture complex liposomal formulations. We are preparing for a commercial launch soon.”

“We are pleased with our partnership with Dr. Reddy’s Laboratories. This approval would not have been possible without their guidance and support,” says Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer, Natco Pharma.

The Doxil® brand and generic had U.S. sales of approximately $196 million MAT for the most recent twelve months ending in March 2017 according to IMS Health*.

Dr. Reddy’s Doxorubicin Hydrochloride Liposome Injection is a sterile, translucent, red liposomal dispersion in 10-mL or 30-mL glass, single-dose vials. Each 10-mL vial contains 20 mg doxorubicin hydrochloride at a concentration of 2 mg/mL. Each 30-mL vial contains 50 mg doxorubicin hydrochloride at a concentration of 2 mg/mL. The following individually cartoned vials are available:

mg in
Vial
Fill Volume Vial Size
20 mg
via
10-mL 10-mL
50 mg
vial
25-mL 30-mL
WARNING: CARDIOMYOPATHY and INFUSION RELATED REACTIONS
See full prescribing information for complete boxed warning.
  • Myocardial damage may lead to congestive heart failure and may occur as the total cumulative dose of doxorubicin HCl approaches 550 mg/m2. The risk of cardiomyopathy may be increased at lower cumulative doses with mediastinal irradiation.
  • Acute infusion-related reactions occurred in 11% of patients with solid tumors. Serious, life-threatening, and fatal infusion reactions have been reported. Medications/emergency equipment to treat such reactions should be available for immediate use.

DOXIL® is a registered trademark of ALZA Corporation.

*IMS National Sales Perspective: Retail and Non-Retail MAT March 2017
RDY-0517-159

Source: PRESS RELEASE
0 comment(s) on Dr Reddy’s gets USFDA Approval for launching Doxorubicin Hydrochloride Liposome Injection in US

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted